A Vision for Gastrin-Releasing Peptide Receptor Targeting for Imaging and Therapy: Perspective from Academia and Industry
J Nucl Med. 2025-05-08; : jnumed.124.269444
DOI: 10.2967/jnumed.124.269444
Lire sur PubMed
https://www.bordeaux-neurocampus.fr/11690
Morgat C(1)(2), Duan H(3), Dalm S(4), Hindié E(1)(2)(5), Günther T(3), Krause
BJ(6), Kramer V(7)(8), Cavelier F(9), Stephens AW(10), Moran S(11), Lamb L(12),
Iagaru A(13).
Author information:
(1)Nuclear Medicine Department, Bordeaux University Hospital, Bordeaux, France.
(2)INCIA, University of Bordeaux, CNRS, EPHE, UMR 5287, Bordeaux, France.
(3)Division of Nuclear Medicine and Molecular Imaging, Department of Radiology,
Stanford University, Stanford, California.
(4)Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The
Netherlands.
(5)Institut Universitaire de France, Paris, France.
(6)Rostock University Medical Center, Rostock, Germany.
(7)Nuclear Medicine and PET/CT Center PositronMed, Santiago, Chile.
(8)Positronpharma SA, Santiago, Chile.
(9)Pôle Chime Balard, IBMM, UMR 5247 CNRS, Université Montpellier ENSCM,
Montpellier, France.
(10)Life Molecular Imaging GmbH, Berlin, Germany.
(11)Novartis, Basel, Switzerland; and.
(12)Clarity Pharmaceuticals Ltd., Sydney, Australia.
(13)Division of Nuclear Medicine and Molecular Imaging, Department of Radiology,
Stanford University, Stanford, California; .
The gastrin-releasing peptide receptor (GRPR) is overexpressed in various
cancers, including prostate cancer, breast cancer, small cell and non-small cell
lung cancer, uterine and ovarian cancer, colon cancer, and gastrointestinal
stromal tumors. This makes GRPR a multicancer target for theranostics, that is,
molecular imaging and therapy. Here, we explore the current state of
GRPR-targeted theranostics from bench to bedside, highlighting the preclinical
development of various GRPR-targeting compounds and clinical applications. We
review the role of GRPR-targeted molecular imaging for all stages of prostate
cancer, breast cancer, and other tumors and provide a quo vadis GRPR. We aimed
to offer a comprehensive overview of GRPR-targeted theranostics to inform
researchers, clinicians, pharma, and regulators of the potential benefits and
emerging opportunities in the pursuit of personalized precision cancer care.
© 2025 by the Society of Nuclear Medicine and Molecular Imaging.
DOI: 10.2967/jnumed.124.269444
PMID: 40341094